Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD) : 7-year follow-up of the European Union Nitric Oxide (EUNO) trial
Greenough, Anne; Decobert, Fabrice; Field, David; Hallman, Mikko; Hummler, Helmut D.; Jonsson, Baldvin; Sánchez Luna, Manuel; Van Overmeire, Bart; Carnielli, Virgilio P.; Potenziano, Jim L. (2020-09-07)
Greenough, A., Decobert, F., Field, D., Hallman, M., Hummler, H. D., Jonsson, B., Sánchez Luna, M., Van Overmeire, B., Carnielli, V. P., Potenziano, J. L., & Mercier, J. (2021). Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union Nitric Oxide (EUNO) trial, Journal of Perinatal Medicine, 49(1), 104-110. doi: https://doi.org/10.1515/jpm-2020-0164
© 2021 Anne Greenough et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0International License.
https://creativecommons.org/licenses/by/4.0/
https://urn.fi/URN:NBN:fi-fe202101212296
Tiivistelmä
Abstract
Objectives: Most studies of inhaled nitric oxide (iNO) for prevention of bronchopulmonary dysplasia (BPD) in premature infants have focused on short-term mortality and morbidity. Our aim was to determine the long-term effects of iNO.
Methods: A 7-year follow-up was undertaken of infants entered into a multicenter, double-blind, randomized, placebo-controlled trial of iNO for prevention of BPD in premature infants born between 24 and 28 weeks plus six days of gestation. At 7 years, survival and hospital admissions since the 2-year follow-up, home oxygen therapy in the past year, therapies used in the previous month and growth assessments were determined. Questionnaires were used to compare general health, well-being, and quality of life.
Results: A total of 305 children were assessed. No deaths were reported. Rates of hospitalization for respiratory problems (6.6 vs. 10.5%, iNO and placebo group, respectively) and use of respiratory medications (6.6 vs. 9.2%) were similar. Two patients who received iNO and one who received placebo had received home oxygen therapy. There were no significant differences in any questionnaire-documented health outcomes.
Conclusions: iNO for prevention of BPD in very premature infants with respiratory distress did not result in long-term benefits or adverse long-term sequelae. In the light of current evidence, routine use of iNO cannot be recommended for prevention of BPD in preterm infants.
Kokoelmat
- Avoin saatavuus [31995]